Neurogene (NGNE) Tax Provisions (2013 - 2014)
Neurogene's (NGNE) quarterly Tax Provisions came in at $185222.0 in Q4 2014, up 420859.09% YoY from N/an in Q4 2013, and up 83533.33% on a QoQ basis from -$222.0 in Q3 2014.
Powered by 
Analysis
Neurogene (NGNE) Tax Provisions (2013 - 2014) Analysis & Trends
Neurogene (NGNE) has 2 years of Tax Provisions data on file, last reported at $185222.0 in Q4 2014.
- Quarterly Tax Provisions rose 420859.09% year-over-year to $185222.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $180000.0 (changed N/A YoY) and the FY2015 annual result came in at $446000.0, up 141.08% from the prior year.
- Tax Provisions grew to $185222.0 in Q4 2014, from -$222.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $185222.0 in Q4 2014 to a low of -$5044.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | 185,222.00 |
| Sep 30, 2014 | -222.00 |
| Dec 31, 2013 | -358,956.00 |
| Sep 30, 2013 | -5,044.00 |